Last updated: February 13, 2026
Overview of NDC 10599-0003
NDC 10599-0003 corresponds to "Fingolimod" (brand name Gilenya), indicated for relapsing forms of multiple sclerosis (MS). It is an oral sphingosine-1-phosphate receptor modulator. Approved by the FDA in 2010, it maintains a significant market share in MS therapy. The drug's patent expired in the U.S. in 2018, though several patents extend exclusivity through secondary filings, with patent cliffs expected to influence pricing and market dynamics.
Market Context
The global MS treatment market was valued at approximately $21 billion in 2022, with the U.S. accounting for roughly 60%. Fingolimod's market share is declining due to biosimilar and generic competition, scheduled to enter the market between 2023-2025, depending on patent litigation outcomes [1].
Current Market Size and Revenue
- In the U.S., Fingolimod generated approximately $1.2 billion in 2022 retail sales.
- The drug maintains high prescriber adoption, especially among patients transitioning from injectables due to ease of oral administration.
- Market penetration is moderated by generics and biosimilar products, with multiple players preparing for entry.
Pricing Trends
- Brand name (Gilenya): Average wholesale price (AWP) is approximately $7,000 per month.
- Generics/Biosimilars: Contracted prices for generic fingolimod could fall below $2,500 per month upon market entry, based on historical biosimilar launches [2].
Key Factors Influencing Price Projections
-
Patent Expiry and Biosimilar Entry
- U.S. patents for Gilenya have faced challenges; some patents expired in 2018, others are contested.
- Biosimilar and generic versions are projected to reduce prices by 35-60% within 1-2 years of launch.
-
Market Competition
- Other oral MS treatments (dimethyl fumarate, teriflunomide, siponimod) contribute to price erosion.
- Adoption rates for biosimilar fingolimod could reach 50% within 3 years of launch.
-
Reimbursement Policies
- Payer negotiations and formulary placements influence final prices.
- Biologics and complex generics often face coverage restrictions, impacting revenue.
-
Regulatory and Legal Environment
- Ongoing patent litigations may delay biosimilar launches.
- Price protections or lowered reimbursement rates may restrict rapid price declines.
Projected Price Trajectories
| Timeline |
Brand Name (Gilenya) |
Estimated Average Wholesale Price (AWP) |
Generic/Biosimilar Price (Post-Entry) |
| 2023 |
~$7,000/month |
N/A |
~$2,500/month (initial launch) |
| 2024 |
~$6,500/month |
N/A |
~$2,200/month |
| 2025 |
~$6,000/month |
~$2,000/month |
~$1,800/month |
As competition intensifies, retail prices are expected to decline further, potentially stabilizing around $1,500 per month by 2027 for biosimilars.
Key Price Drivers
- Patent expiration in 2018 initially lowered prices; further reductions expected with the entry of biosimilars.
- Volume growth for MS treatments supports revenue, even as unit prices decline.
- Reimbursement strategies will impact net prices and market penetration.
Risks to Price Stability
- Delays or blocking of biosimilar entries due to patent litigation.
- Manufacturer price promotions or rebates that inflate net prices.
- Shifts in the MS treatment algorithm favoring newer therapies.
Summary
The market for fingolimod (NDC 10599-0003) is in transition from high-priced patented formulations toward more affordable biosimilars. Prices are projected to decline steadily over the next five years, with significant reductions once biosimilar products gain widespread acceptance. Market share will be influenced by regulatory outcomes, prescriber preferences, and payer policies.
Key Takeaways
- Market size remains substantial, with a U.S. retail revenue of around $1.2 billion annually.
- Patent expirations and biosimilar entries are primary catalysts for price reductions.
- Pricing decline expected from ~$7,000/month for brand to ~$1,500/month for biosimilars by 2027.
- Competitive landscape includes multiple MS therapies, which may accelerate price erosion.
- Reimbursement policies will significantly influence actual net prices and accessibility.
FAQs
1. When are biosimilar fingolimod products expected to enter the market?
Entry is projected between 2023 and 2025, contingent upon patent litigation outcomes.
2. How will biosimilar entry affect overall market revenue?
Prices are expected to decline by approximately 35-60%, leading to decreased revenue per unit but potential volume increases.
3. What are the main patent challenges facing fingolimod?
Multiple secondary patents have delayed biosimilar entry; ongoing litigation could further extend exclusivity.
4. How do reimbursement policies influence pricing?
Reimbursement rates and formulary placements determine final patient access and net revenue, often limiting price drops.
5. What market segments could see the most significant price reductions?
Generic and biosimilar segments will experience the largest decreases post-approval and market penetration.
References
- IQVIA, "MS Market Analysis," 2022.
- GoodRx, "Average Prices for MS Drugs," 2023.
